Born in India, Prof. A.K.Ganguly earned his undergraduate
and master’s degrees in chemistry from Delhi University,
where he also completed his Ph.D. in organic chemistry in
1959 under the supervision of Prof. T.R.Seshadri. As a testament
to his high level of scholarship, he then received the prestigious
1851 Exhibition Scholarship, awarded annually by the Royal
Commission, Great Britain, to only one student of science
from India to study in England. He attended the Imperial College
of Science and Technology, London, where he obtained his second
Ph.D. in chemistry in 1961. There, he studied under the supervision
of Sir Derek Barton, a Nobel Laureate in chemistry, whom Dr.
Ganguly credits as the greatest influence of his scientific
After finishing his studies at the Imperial College of Science
and Technology Prof. Ganguly returned to India to work for
Glaxo Laboratories in Bombay. After a brief period of stay
at Glaxo he moved to the Ciba Research Center, also in Bombay,
where he established a fruitful collaboration with Prof. T.R.Govindachari.
Prof Ganguly immigrated to the United States in 1967 and worked
with Sir Derek at the Research Institute of Medicine and Chemistry,
Cambridge, Massachusetts before joining the Schering-Plough
Research Institute, Kenilworth, NJ in 1968 as a Senior Scientist.
At Schering-Plough Research Institute he progressed to the
position of Senior Vice President of Chemical Research in
which capacity he directed all aspects of Chemical Research
at the institute. In September 1999 he joined Stevens Institute
of Technology, Hoboken, NJ where he is presently a Distinguished
Research Professor of Chemistry and Co-Director in the Department
of Chemistry and Chemical Biology. He teaches Medicinal Chemistry
and directs research programs for graduate students at Stevens.
Prof. Ganguly has made many significant contributions in drug
discovery. He is associated with the discoveries of Ezetimibe
(Zetia), a cholesterol absorption inhibitor; Noxafil (Posaconazole),
a potent antifungal; Lonafarnib (Sarasar), a highly selective
farnesyl protein transferase inhibitor for the treatment of
cancer and SCH 503034, an orally active inhibitor of Hepatitis
C Virus protease. Prof. Ganguly is also recognised for his
many contributions towards synthesis of other biologically
active molecules. In the area of infectious diseases, Prof.
Ganguly’s contribution towards solving the very complex
structure of Ziracin, a potent antibiotic which is active
against Methicillin resistant Staph. aureus and synthesis
of Penem antibiotics are widely recognized in the scientific
Prof. Ganguly has published two hundred thirteen papers
and is a co inventor of eighty-seven patents, and has been
a plenary lecturer at many international meetings. He has
received several awards, a partial list of which is shown
1. Recipient of Professor Seshadri Memorial Award for the
2. Charles Sabat Lecturer, Rutgers University, 1987.
3 Recipient of "Outstanding Scientist Award" given
by the Association of Scientists of Indian Origin in America,
4. Third Herman S. Bloch Memorial Lecturer at The University
of Chicago, 1995.
5. Ranbaxy Science Foundation Award for Pharmaceutical Sciences,
6.. Gurbax Singh Memorial Award Lecture for Biomedical Sciences,
7. E. B. Hershberg Award for important discoveries in medicinally
active substances, American Chemical Society, 2003.
8. Presidential Lecture at the Acadia University, Canada,
9. Doctor of Engineering (Honoris Causa) from Stevens Institute
of Technology, 2004.
10. Lifetime achievement award, Indian Chemical Society, 2004
11. Thomas Alva Edison Award, 2006
12. Hall of Fame, Medicinal Chemistry, American Chemical Society,
Prof. Ganguly remains as a consultant at Schering-Plough
Research Institute .